Skip to main navigation

About

Strategic Assets

Team

Strategy

Investor Relations

Investor Overview Press Releases Corporate Presentation Corporate Governance

Overview
Board of Directors
Management
Committee Composition

Stock Information

Overview
Analyst Coverage

SEC Filings Email Alerts Subscription Contact Us

Contact Us

Presentations & Events

Upcoming Events

There are no upcoming events scheduled at this time.

Presentations

Innoviva Corporate Presentation - January 2023

Scientific Posters

Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Population pharmacokinetic (PPK), pharmacokinetic/pharmacodynamic attainment (PTA), clinical pharmacokinetic/pharmacodynamic (PK/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii–calcoa

Source

durlobactam (etx2514)

Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

Source

durlobactam (etx2514)

Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Source

durlobactam (etx2514)

Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

Source

durlobactam (etx2514)

Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Source

durlobactam (etx2514)

Characterization of colistin-resistant (COL-R) Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent global phase 3 trial (ATTACK)

Source

durlobactam (etx2514)

Archived Events

Date	Event	Supporting Materials
Sep 14, 2022 at 11:10 AM EDT	Morgan Stanley 20th Annual Global Healthcare Conference	Listen to webcast

Investor Relations
Press Releases
Corporate Presentation
Corporate Governance
Stock Information
- Overview
SEC Filings
Email Alerts Subscription
Contact Us

Innoviva

Mar 25, 2023 12:12 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Sign up to receive important email alerts & updates from Innoviva.

Download Library
RSS News Feeds
Print

© 2023 Innoviva. All rights reserved. Terms & Conditions | Privacy Policy | Contact © 2023 Innoviva. All rights reserved.